Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Jaguar Health, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.14
4.36
4.42
5.78
9.39
4.34
12
9.76
11.7
11.5
Cost of revenue
0.05
0.88
2.77
3.82
3.28
2.33
2.02
2.04
1.96
3.77
Gross profit
0.09
3.48
1.65
1.96
6.11
2
9.94
7.72
9.73
7.74
Research and development
7.21
4.27
5.15
5.82
6.41
15.1
17.6
18.6
16.5
25
Selling and marketing
0.49
3.08
9.83
6.94
6.61
8.89
8.84
6.46
7.69
9.24
General and administrative
5.98
11.2
12.3
13.5
14.4
17.1
17.9
16.6
16.3
18.6
Operating expenses
13.7
38.6
35.2
Operating income
-13.6
-34.2
-30.8
-28.9
-26.6
-40.7
-34.4
-34.3
-30.8
-45.9
Interest expense
0.99
1.21
2.63
5.73
2.79
8.42
12.7
6.38
0.23
0.07
Other non-operating income
-0.01
0.09
0.32
0.08
0.19
-0.77
0.95
0.2
0.05
0.04
Pre-tax income
-14.7
-35.1
-32.1
-38.5
-33.8
-52.6
-48.4
-41.9
-39.3
-54
Income tax
-13.2
0.01
0
0
0
0
0
0
Net income to minority interests
-0.01
-0.94
-0.6
-0.76
-0.56
Net income
-14.7
-22
-32.1
-38.5
-33.8
-0.05
-0.05
-0.04
-38.5
-53.6
EBITDA
-13.5
-33.7
-29.5
-27.2
-24.9
-39
-32.4
-32.3
-28.9
-44
EPS, basic
-471,856,050.00
-178,257,222.00
-51,433,734.00
-3,023,540.00
-335,577.00
-131,993.00
-54,132.00
-2,678.00
-130.69
-22.97
EPS, diluted
-471,856,369.00
-178,256,851.00
-51,433,795.00
-3,023,543.00
-335,576.00
-131,993.00
-54,132.00
-2,678.00
-130.69
-22.97
Shares, basic (weighted)
0
0
0
0
0
0
0
0.02
0.29
2.33
Shares, diluted (weighted)
0
0
0
0
0
0
0
0.02
0.29
2.33
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.95
0.52
2.57
3.5
8.09
17.1
5.47
6.47
8
0.97
Receivables
0
0.47
1
1.69
2.1
1.71
1.88
1.97
1.53
1.52
Inventory
0.41
2.07
3.34
2.13
2.78
4.9
7.02
9.19
10.3
8.6
Other current assets
0.3
0.5
1.24
1.26
2.36
4.34
7.36
10.1
12.2
2.22
Total current assets
2.56
3.8
8.15
9.52
17.8
28.4
22.3
28
32.2
20.3
Property, plant and equipment
0.89
1.22
0.76
0.71
0.68
0.65
0.56
0.5
0.46
0.46
Lease right-of-use assets
1.08
1.14
1.18
0.94
1
Goodwill
0
5.21
5.21
Intangible assets
33.4
31.7
26
24.3
22.7
22.4
20.1
18.5
16
Total assets
3.56
43.6
41
36.4
42.8
53.3
47.5
50.8
53.4
38.3
Accounts payable
0.52
7.35
5.41
5.35
4.76
4.93
5.81
4.97
5.29
8.69
Accrued liabilities
0.58
2.2
4.94
2.92
4.49
7.12
8.17
3.8
1.91
4.17
Deferred revenue
0.22
0.18
0.17
0.17
Short-term debt
1.92
1.61
Total current liabilities
4.19
15.4
26.7
15.4
13.2
15.5
30.3
14
19.7
40.7
Long-term debt
1.82
11
0.45
12.4
25
17.7
31
23.5
15.1
Lease liabilities
0.92
0.73
0.89
0.69
0.89
Total liabilities
6.02
26.4
26.7
15.8
25.6
41.4
48.8
45.9
44.4
57
Total debt
3.74
12.6
Paid-in capital
38
79.7
99.9
142
184
231
267
314
354
381
Retained earnings
-40.4
-62.4
-94.6
-133
-167
-219
-267
-308
-346
-400
Other comprehensive income
-0.68
-0.65
-0.47
-0.83
Shareholders' equity
-2.45
17.3
5.38
10.7
17.2
Minority interests
0.24
-0.7
-0.06
-0.79
-1.4
Total equity
-2.45
17.3
5.38
10.7
17.2
11.9
-1.36
4.9
6.49
-18.7
Total liabilities and equity
3.56
43.6
41
36.4
42.8
53.3
47.5
50.8
53.4
38.3
Shares outstanding
0
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-14.7
-22
-32.1
-38.5
-33.8
-52.6
-48.4
-41.9
-39.3
-54
Depreciation and amortization
0.05
0.58
1.32
1.74
1.73
1.72
1.98
2.01
1.9
1.91
Stock-based compensation
0.72
0.81
2.02
2.99
2.82
3.97
3.32
2.11
1.64
0.83
Deferred income tax
5.64
-13.2
0
0
0
0
0
0
0
0
Change in receivables
0.05
-0.17
-0.53
-0.7
-2.84
2.82
-0.17
-0.09
0.44
0.01
Change in inventory
-0.18
0.13
-1.27
1.21
-0.65
-2.12
-2.12
-2.17
-1.16
-0.25
Change in payables
-0.03
4.19
-1.94
-0.06
-0.74
0.16
0.9
-0.86
0.33
3.35
Cash from operations
-14.4
-9.82
-22.7
-20.5
-15.3
-35
-33.1
-33.2
-29.4
-23.7
Capital expenditures
-0.1
-0.01
-0.01
-0.01
-0.08
-0.02
Acquisitions
-1.56
Cash from investing
2.38
-1.56
-0.01
-0.01
-0.01
-1.68
-0.23
-0.04
Debt issued
12.3
11
Debt repaid
-2.49
-2.42
-1.69
-0.1
-0.41
-0.1
Stock issued
5.06
0
Share buybacks
-0
Cash from financing
5.28
10.7
24.5
21.8
19.5
43.9
23.2
34.2
31.2
23.7
Net change in cash
-6.75
-0.7
1.81
1.32
4.21
8.96
-11.6
1
1.53
-0.17
Free cash flow
-14.5
-22.7
-15.3
-35
-33.2
-29.4
Interest paid
0.48
0.14
0.76
0.03
0.02
0.04
0.01
0.02
Income taxes paid
0.48
0.23
0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.70 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
82.3%
Gross profit / revenue.
Operating margin
-93.1%
Operating income / revenue.
EBITDA margin
-86.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-132.7%
Pre-tax income / revenue.
Net margin
-188.5%
Net income / revenue.
Operating cash flow margin
-24.0%
Cash from operations / revenue.
Return on assets (ROA)
-153.3%
Net income / average total assets.
R&D / revenue
90.7%
Research and development expense / revenue.
Stock-based pay / revenue
2.1%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
6.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-1.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-1.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
4.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-20.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-8.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
4.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-28.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-6.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-2.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
691.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1,285.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
626.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.69x
Current assets / current liabilities.
Quick ratio
0.15x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.15x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
85.6%
Total liabilities / total assets.
Interest coverage
-25.9x
Operating income / interest expense.
Working capital
-$7.8M
Current assets - current liabilities.
Goodwill and intangibles / assets
44.1%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.81x
Revenue / average total assets.
Fixed asset turnover
66.7x
Revenue / average property, plant and equipment.
Inventory turnover
0.67x
Cost of revenue / average inventory.
Days inventory
543 days
365 x average inventory / cost of revenue.
Receivables turnover
3,477x
Revenue / average receivables.
Days sales outstanding
0 days
365 x average receivables / revenue.
Days payables
356 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
187 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$64.79
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/S
1.36x
Market cap / revenue.
EV/Sales
1.22x
Enterprise value / revenue.
Earnings yield
-138.6%
Net income / market cap (the inverse of P/E).
What was Jaguar Health, Inc.'s revenue in fiscal 2025?
Jaguar Health, Inc. reported revenue of $11.5M for fiscal 2025, 1.5% lower than the year before.
Was Jaguar Health, Inc. profitable in fiscal 2025?
No. It reported a net loss of $53.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.